Hong G, Zhao Y, Hou X. Impact of four-week rifaximin treatment on abdominal symptoms, psychological state and gut microbiome in diarrhea-predominant irritable bowel syndrome: a pilot study. Eur J Pharmacol 2025;1007:178271.
PMID: 41110752